Breast Cancer
Conditions
Brief summary
The purpose of this study is to determine whether oral administration of curcumin causes biological changes in primary tumors of breast cancer patients.
Detailed description
The purpose of this study is to determine whether oral administration of Curcuma longa extract causes biological changes related to apoptosis (DNA fragmentation) and cell proliferation (Ki67) in primary tumors of breast cancer patients.
Interventions
DRUGCurcumin
Curcumin is an extract from turmeric
Sponsors
Medical University of South Carolina
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed invasive breast cancer (stages I, II, or III) with primary tumor(s) ≥ 1.0 cm on mammogram, ultrasound, MRI, or physical exam 2. 18 years of age or older 3. Subject must understand risks and benefits of the protocol and be able to give informed consent 4. Women of childbearing potential (WOCBP) must agree to use an approved form of birth control and to have a negative pregnancy test result within 14 days of registration. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes Approved forms of birth control: * combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intra-vaginal, or transdermal) * progestogen only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable) * intrauterine device, intrauterine hormone-releasing system * bilateral tubal occlusion/ligation * vasectomized partner * barrier contraception * sexual abstinence 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Adequate hematologic and end organ function 7. Ability and capacity to comply with the study and follow-up procedures 8. Subjects must be scheduled for surgery at MUSC no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1 9. At least 6 sections of unstained slides should be obtained. If sufficient slides or tissue is unavailable, the patient will be excluded from the trial
Exclusion criteria
1. Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy 2. Subjects with end-stage kidney disease and/or grade II liver dysfunction 3. Subjects who are pregnant or are lactating. 4. Subjects with bile duct obstruction, gallstones, predisposition to kidney stones(39), or gastrointestinal disorders such as stomach ulcers and hyperacidity disorders(40) 5. Subjects taking anti-coagulants or platelet inhibitors 6. Subjects taking drugs metabolized by CYP3A4, CYP1A2, and CYP2A6 enzymes 7. Subjects taking drugs that interact with P-glycoprotein (P-gp) 8. Subjects taking any of the medications listed under Other Herb-Drug interactions according to the Memorial Sloan Kettering Cancer Center in section 5.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in tumor proliferation rate | Up to 56 days | Change in tumor proliferation rate will be based on apoptosis (DNA fragmentation) and cell proliferation (Ki67) assays in biopsies pre and post treatment with curcumin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse events reported | up to 84 days | Safety data will be tabulated by type and grade of adverse event and will use CTCAE v. 4.0 |
Countries
United States
Outcome results
None listed